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Requisite models for strategic 
commissioning: the example of type 1 
diabetes
Abstract 
A developing emphasis of health care reforms has been creating organisations with 
responsibilities for strategic commissioning of services for defined populations.  Such 
organisations must set priorities in aiming to meet their populations’ needs subject to 
a budget constraint.  This requires estimates of the health benefits and costs of 
different interventions for their populations. This paper outlines a framework that 
does this and shows how this requires modelling to produce estimates in a way that is 
transparent to commissioners, of requisite complexity to produce sound estimates for 
priority setting using routinely available data.  The example illustrated in this paper is 
an intervention that would improve glucose control in the English population with 
type 1 diabetes. It takes many years for a change in glucose management to deliver 
maximum benefits; hence the intervention is not good value-for-money in the short 
run. We aim to give a more strategic view of the costs and benefits modelling costs 
and benefits in a steady-state model which suggests that the intervention is good 
value-for-money in the long run.
Keywords: resource allocation, population health, DALYs, QALYs, commissioning, 
strategic purchasing, type 1 diabetes, microvascular complications, intensive glucose 
control.
Manuscript (must not contain author information)
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Requisite models for strategic 
commissioning: the example of type 1 
diabetes
Introduction
Cost-effectiveness analysis (CEA) and disease modelling have grown apace in the hope of 
informing policy formation, however many authors have questioned their actual contribution to 
the development and implementation of policies [1-5]. This paper develops a framework for 
CEA and cost-effectiveness analysis to provide information for organisations responsible for 
strategic commissioning of health services for defined populations and illustrates its use by 
modelling intensive glucose control in type 1 diabetes in England.  Strategic commissioners (or 
purchasers) have emerged in reforms of health care, which are required to assess needs of 
populations, determine the optimal way of meeting these needs, and accordingly contract with 
providers of different services.  This is currently the task of Primary Care Trusts (PCTs) in the 
National Health Service (NHS) in England [6] and Local Health Integration Networks (LHINs)  
in Ontario  [7].  The second section of this paper outlines the framework we have developed to 
help strategic commissioners set priorities.  The third section illustrates how this framework was 
used in modelling type 1 diabetes.  The final section discusses the results and implications of 
our framework for disease modelling.
Framework of analysis
The mainstream evaluation framework in economic evaluation for priority setting is that of 
Quality-Adjusted Life Years ([8, 9]; see [10, 11] for a review of proposed, albeit less 
widespread alternatives). A Quality-Adjusted Life Year (QALY) is a year weighted for quality 
of life, with a weight of one for perfect health and zero for death.  QALYs are used to compare 
alternative interventions and to prioritize cost-effective interventions for funding. The cost-
effectiveness of an intervention is measured by the ratio between its added value in terms of 
health benefits and its incremental cost compared to an alternative, the “incremental cost-
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effectiveness ratio” or simply “cost/QALY”. Interventions with a lower cost/QALY represent 
better value for money because a smaller investment is needed to produce a unit of benefit or, 
alternatively, more QALYs can be achieved per unit spent. A different measurement tool that 
raised a heated debate is the concept of Disability-Adjusted Life Years (DALYs) to estimate the 
Burden of Disease (BoD) in a population [12-17]. DALYs are a form of summary measures of 
population health and combine information on mortality and morbidity (for a review of 
alternative measures see [18]) and consist of the sum of Years of Life Lost (YLLs) from 
premature mortality and Years Lived with a Disability (YLDs), in which each year of life is 
weighted for disability with a weight of zero for perfect health and one for death.    These 
different approaches have subsequently been developed to converge to produce information on 
costs and benefits of interventions in the population in terms of reductions in BoD measured in 
DALYs [19-21], or gains in health, measured in QALYs [22-25].  
Beside common serious methodological, ethical and empirical problems [10, 18], each 
approach, as originally developed, was subject to different limitations as bases for setting 
priorities. The methodology of Cost/QALY was designed for marginal analysis: it does not 
distinguish interventions of low cost and low benefit from those of high cost and high benefit; 
does not tell us whether the bulk of resources are being currently used effectively [26, 27]; nor 
the number of people affected by an intervention.  The value of reporting on the scale of the 
intervention has been highlighted by Murray and Lopez [17]: “If there are fixed assets, other 
than disposable dollars, limiting the feasible combinations of interventions that can be delivered 
– real-world examples include the attention of senior Ministry of Health decision-makers or the 
political commitment of government leaders –, then these should be devoted not just to the most 
cost-effective interventions but to those cost-effective interventions with the potential to effect 
substantial improvements in population health status’. The standard approach to estimating BoD 
in DALYs, however, gives estimates of that which exists given the current delivery of health 
care, and hence is best described as the ‘current’ BoD.    Estimates of the current BoD in 
DALYs are of no value in themselves, nor a good guide on the potential benefit from an 
intervention.  Hollinghurst et al.  [28] estimate the current BoD and the potential benefits from 
interventions in the South West of England.  Estimates varied greatly across different diseases  
and showed  that, although the current BoD of heart diseases was higher than that of depression, 
the DALYs that are potentially avoidable by improving treatment of depression were much 
more than those of improving treatment of heart diseases.  To set priorities using DALYs, we 
require information on benefits and costs, but to interpret the relationship between DALYs and 
costs, we need to distinguish between estimates of three different components of BoD [28-30]: 
(i) DALYs ‘avoided’ from the current delivery of health care which with their costs indicate 
cost-effectiveness of current practice; (ii) DALYs ‘avoidable’ through improving treatment 
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(coverage, appropriateness or compliance) which need to be put alongside estimates of their 
costs to indicate potential cost-effectiveness of changing practices; and (iii) DALYs that are 
‘unavoidable’ and cannot be reduced given current evidence, and are hence irrelevant to 
assessments of setting priorities among available interventions. 
To set priorities for populations we require methods that draw on both cost/QALY and DALYs 
by applying the framework of cost-effectiveness to populations in order to estimate the 
‘avoidable’ burden of disease [29].  The concept of ‘avoidable’ burden of disease builds on the 
idea of using ‘avoidable mortality’ to assess the use of resources among different health care 
services [31-33] and combines it with DALYs to estimate both mortality and morbidity 
avoidable through an intervention. This has been the common basis for three different recent 
sets of studies: cost-effectiveness of treating mental illness in Australia [34]; WHO’s project for 
Choosing Interventions that are Cost Effective [21, 27, 35]; and estimates of NHS productivity 
that sought to estimate gains in QALYs for the population of England [23-25, 36].
To deal with costs and health benefits occurring at different points in time, manuals of cost-
effectiveness recommend the use of a common discount rate, but acknowledge that theory and 
empirical evidence on the relationship between interest rates and rates of time preference is 
unsettled. For strategic commissioners, the cost-effectiveness of a health intervention based on 
its derived present value is difficult to interpret and use: they are allocated annual budgets and 
cannot easily translate results from economic evaluation on the financial impacts in the short 
and in the long term. This is nicely illustrated by intensive glucose control for type 1 diabetes.  
This is because, although some evidence suggests that over the patient’s lifetime this is more 
cost-effective than conventional care [37-40], its funding will cause an immediate increase in 
costs and delayed benefits. This paper proposes a different approach by measuring impacts on 
population health and on the commissioner’s budget in the short- and long-run. 
Modelling type 1 diabetes
The Disease and Interventions 
Diabetes mellitus is one of the most common chronic diseases and the diabetic population in 
England is estimated to be about 2.2 million  [41].  Of these, 2 million have type 2 diabetes, 
which is characterised by insulin resistance and usually diagnosed in the middle aged or elderly; 
and about 170,000 have type 1 diabetes, which is characterised by an absolute deficiency of 
insulin and is usually of rapid onset.
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The evidence is that only a minority of people with type 1 diabetes have blood-glucose 
concentrations below the recommended levels (Figure 1) [42]; there is a well-known association 
between poor glucose control and the development of microvascular complications, i.e. eye, 
kidney and nerve damages that could lead to blindness, dialysis and amputation [40, 43, 44]
hence, these people are expected to develop complications. A large longitudinal study has 
shown, however, that it is possible to reduce the levels of glucose concentration by providing 
intensive and personalized advice on insulin doses, diet and exercise and that, over time, this 
leads to a significant reduction in microvascular complications [40, 43, 44].  There is also some 
evidence that the intervention is cost-effective according to standard economic evaluation both 
in type 1 [37-40] and in type 2 diabetes [e.g. 45, 46]. However, microvascular complications are 
progressive, appear after several years after the onset of diabetes and tend to degenerate over 
time. The typically degenerative nature of these complications poses a particular challenge in 
designing policies for these patients: those who already have moderate complications will have 
limited benefits from intensive glucose therapy, as the damage is already present and cannot 
usually be reversed; the full benefits are for those who receive intensive glucose control from 
the early stages of their diabetes only, but there are long time lags between the start of the 
therapy and its benefits in terms of reduced complications. 
----------------Figure 1 Proportion of type 1 diabetes population with glucose levels within the 
recommended level, by age group----------
Modelling requirements of our framework 
Our framework required estimates of the BoD from type 1 diabetes that is ‘avoidable’ through 
intensive glucose control by modelling the relationships between better glycaemic control and: 
reduced risks of developing renal, eye or neural complications; and slower progression from 
mild to severe stages after the onset of the complication; and lower mortality rates.  We required
estimates of the current BoD and that which is ‘avoidable’ from in terms of:
 Deaths;
 Years of Life Lost (YLLs) – the residual life expectancy at the age of the ‘avoidable’ 
death according to local life tables; and
 Years Lived with a Disability (YLDs) using disability weights developed by the Dutch 
Disability Weight study [47]; 
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 DALYs (the sum of YLLs and YLDs), with and without discounting, using a 3.5% 
discount rate [48].
We also required estimates of average annual net costs of:
 expenditure each year, for the whole of the diabetic population, drugs, equipment; 
monthly specialist visits and measurement of HbA1c , less 
 savings due to intensive glucose control from reductions in the costs of treating the 
sequelae of diabetes, renal disease (including dialysis), eye disease, and diabetic foot 
(including amputation).
We also required estimates of the short- and long-run impacts of intensive glucose control:
 over the next five years, assuming a policy in which intensive glucose control  was 
introduced for all patients regardless of the stage of their disease, in which we modelled
changes in the current population from aging and death, but omitted births (this is 
known as a ‘closed population model’); and 
 in the long run, in a future ‘steady state’, in which all patients would have intensive 
glucose control at the onset of the disease, in which we modelled a population cohort of 
new cases of different ages and simulated changes over time by assuming that the total 
size and age distribution of the population was stable.  
Although five years was an arbitrary choice, it reflects a period between the immediate and long 
run and corresponds to the time horizon recommended for strategic planning in the English 
NHS (supplemented by yearly reviews) and is similar to the Ontarian 4-year typical time 
horizon with yearly reviews.  The steady state scenario gives indications of the expected annual 
health benefits and costs for a stable intervention and has been used in the past to evaluate 
services with long time lags as diabetes [49, 50].
To compare the health benefits with the net cost of the intervention, we attached a monetary 
value to life. We assumed a theoretical equivalence between a year of life in full health and a 
year of life free of disability [51] and used the putative threshold of the National Institute for 
health and Clinical Excellence, which on average judges cost-effective a health intervention that 
costs less than £30k per QALY. We ran a sensitivity analysis on the value of health benefits. 
In this paper we investigate the adequacy of a simple disease model within our framework of 
analysis. To be useful for informing strategic commissioning, we required a transparent, simple 
model, using routinely-available data, that would produce approximate estimates that would 
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indicate orders of magnitude for comparison with other interventions within and across different 
diseases at the population level. Most of the diabetes models that have been developed 
understandably focus on type 2 diabetes (based on the pioneering work by Eastman and 
colleagues [45, 52]), but some like the Archimedes, the CORE or the EAGLE model are 
designed for both type 1 and 2 [53-55]. We tested the adequacy of our model through 
validation, sensitivity analysis and comparing results with those from more sophisticated 
models. The model we developed is requisite for our purpose and parsimonious  [56, 57].
We modelled diabetes as a Markov chain, which makes the simplifying assumption that the 
probability of transition from disease state A to disease state B does not depend on the patient’s 
history before arriving in state A. However, the incidence of microvascular complications 
correlates significantly with diabetes duration [58]; we divided the population in 5-year age 
groups to allow the use of a different set of transition probabilities for each one. The probability 
of death is dependent both on age and degree of severity of complication. The incidence of 
complications and their progression rates vary with age, but as there are no routinely available 
data on these, we assumed no incidence of microvascular complications before the age of 15 
and lower incidence rates in young adults compared to older ones. The specifications for the two 
models are outlined in Figure 2.  A description of the key assumptions and an evaluation of the 
data are given in Tables 1 and 2.  We estimated the BoD: from higher mortality (deaths and 
YLLs) from all causes; and disability (YLDs) associated with microvascular complications, 
diabetic nephropathy, retinopathy and diabetic foot; but not from acute diabetic events 
(ketoacidosis), non-fatal myocardial infarctions, non-fatal strokes and coronary 
revascularisations. Although we did not model patients with cerebrovascular complications 
explicitly, deaths caused by these complications are accounted in the YLLs from all causes.
The model can be run for any local population and we have used it for England, ten different 
PCTs in the South-East of England and two PCTs in central London. However, the 
demographic differences across these PCTs did not have a significant impact on the relative 
magnitude of results. In this paper we discuss estimates for the population of England.
----------------Figure 2 Base structure of the model for diabetic nephropathy (left) and diabetic 
retinopathy & diabetic foot (right)---------------------
-------------Table 1 Main model assumptions-----------
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First five years
The model of the first five years tracked 100 birth cohorts, i.e. the population from ages 0 to 99 
over five consecutive years.  The distribution by age of the initial population was that in 
England in 2003.  Estimates of BoD in DALYs were calculated by equation (1):
(1)  YLDsYLLsDALYs
  
 


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0 0
)1(
1
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 
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
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0 0
5
1
*)(*),,(
j
k
s
r
i
ri eswsjiAe ………………….. (1)
where:
 i is the index for the years over which the model is run;
 j is the index for the cohorts (j is the initial cohort age);
 s is the index for the degree of severity of the condition;
 r is a discount rate.  The model was run with r=0 (which corresponds to no discounting) 
and with r=3.5% (giving discounted values);
 ),,( sjiA is the number of the population with diabetes at stage s in year i of cohort j;
 ’( i+j, s) is the excess mortality rate from type 1 diabetes  with degree of severity s for 
the jth cohort in year  i (by which time the members of this cohort will be [i+j]  years 
old);
 L ( i+j ) is the residual life expectancy of the jth cohort in year  i. (we assume that L is 
residual life expectancy based on local life tables for someone i+j years old);
 w(s) is the disability weight associated with degree of severity s.
At the core of the model, was the system of difference equations that model the evolution of two 
populations, A and N.  A(i, j, s) was the population with type 1 diabetes in degree of severity s, 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
9
N(i, j) was the population without type 1 diabetes (both constituted the jth cohort in the ith year 
of modelling). 
The population with type 1 diabetes in the jth cohort in the (i+1)th year of modelling [A(i+1, j, 
s)]  was derived from populations with type 1 diabetes [A(i, j, s) and A(i, j, s-1)] and without 
type 1 diabetes [ N(i, j)], in the jth cohort in the ith year of modelling, and estimated by equation 
(2):
     sjisjisjiAsjiA s ,)1,(1),,(,,1 
  sjijiNsjisjiA s ,),()1,()1,,(    ……………………. (2)
for all j (0 to 99) and for all  i (1 to 5) where:
 )1,(  sjis  is the transition probability from stage s to s+1;
  sji ,  is the death rate from type 1 diabetes  in stage s for the jth cohort in year i
(and is equal to age-specific mortality rate for the population without the condition, 
 ji  , plus the excess mortality rate from type 1 diabetes  with degree of severity s
in year i of the cohort jth, ’( i+j, s));
 )1,(  sjis is the transition probability from stage s-1 to stage s;
  sji ,  is the incidence rate of new cases of type 1 diabetes  at stage s from 
population N, where    jisji
s
  , .
The population without type 1 diabetes in the jth cohort in the (i+1)th year of modelling [N(i+1, 
j)], was derived from the population without type 1 diabetes in the jth cohort in the ith year of 
modelling [N(i, j)], were and estimated by equation (3):
      jijijiNjiN  1),(,1 ………………………. (3)
for all j (0 to 99) and for all  i (1 to 5) where:
  ji   is incidence rate of new cases with type 1 diabetes for the jth cohort in year i;
  ji   is death rate for of the population without type 1 diabetes  in year i.
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The model required estimates of the initial populations without and with type 1 diabetes: N(0,j) 
and A(0,j). These were derived using data on the 2003 population in England [59] and 
prevalence estimates published by Harvey et al. [60].  We did not find data on the distribution 
of the population with type 1 diabetes (A(0,j)) in terms of degrees of severity by age of renal and 
eye complication.  We estimated these distributions by generating a hypothetical birth cohort of 
100,000 persons and simulating their aging, deaths and progression to and through diabetes over 
100 years.  The dynamic of the hypothetical cohort was modelled with a Markov-chain model 
that used the same transition probabilities of the main model presented in this paper.  We 
assumed that the proportion of diabetic patients with degree of severity s at period t of the 
hypothetical cohort simulation was representative of the proportion of diabetic patients aged t in 
the current English diabetic population. We subject the resulting initial condition to validation.
Figure 2 outlines the progression of type 1 diabetes in the stages of nephropathy (left panel) and 
retinopathy (right panel). The stages of nephropathy are: 
 microalbuminuria, i.e. an increased concentration of the protein ‘albumina’ in the urine;
 macroalbuminuria, i.e. overt proteinuria or ‘clinical nephropathy’, and 
 end stage renal disease (ESRD). 
Each of these stages is also associated with increased mortality rates, mainly due to 
cardiovascular disease [61-64]; and these are particularly high for macroalbuminuria [65, 66]. 
The progression of retinopathy to blindness is also associated with a higher mortality rate 
compared to the non-diabetic population. The effect of glycaemic control was modelled through 
transition probabilities , which are lower for diabetic patients under intensive glucose control 
compared to conventional care, which means there is a slower progression of the disease to and 
through microvascular complications (see Appendix).
The retinopathy model also estimated the BoD from ulcers, sores and amputation using the 
incidence rates of these complications associated with different degrees of retinopathy [67] (see 
Appendix). The Diabetes Control and Complications Trial (DCCT study) does not report the 
reduction in lower extremity amputation rates. We built on the association between degrees of 
severity in retinopathy and lower extremity amputation [67]. We made two assumptions: first, 
poor glucose control is an underlying cause of both diabetic retinopathy and diabetic foot; 
second, the association between degree of severity of retinopathy and diabetic foot is the same 
in the intensive glucose control and in the conventional treatment group (keeping constant the 
provision of other treatments, e.g. laser treatment). For instance, the 4-year incidence of lower 
extremity amputation is 7.8% in patients with proliferative diabetic retinopathy (PDR).  
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However, fewer people have PDR with intensive glucose monitoring and control than with 
conventional therapy.  The model we built did not model neuropathy and diabetic foot explicitly 
and would be unsuitable to measure the impact of other specific interventions (e.g. changes in 
laser therapy).
There are interdependencies among all complications that cannot be represented in a simple 
spreadsheet model like ours (to represent them, the CORE model builds on fourteen sub-models 
and the Archimedes model generates the biology of a virtual patient directly rather than 
modelling distinct health states).  We combined the nephropathy and retinopathy/diabetic foot 
models to estimate YLLs and YLDs from type 1 diabetes as follows:  
 YLLs based on deaths from the nephropathy model, because albuminuria is the best 
predictor of all-cause mortality in type 1 diabetes [65]. These deaths includes those 
from macrovascular complications such as myocardial infarctions and strokes;
 YLDs from the nephropathy model (for macroalbuminuria and ESRD);
 YLDs from the retinopathy-diabetic foot model (for uncomplicated type 1 diabetes, 
moderate and severe visual impairments, sores, ulcers and lower extremity amputation.
The current BoD and health gains from reduced non-fatal macrovascular complications have not 
been estimated here.
The steady-state 
The model of the steady-state estimated the BoD of type 1 diabetes for one year with a set of 
initial conditions A(j,s) based on the age specific profile of a hypothetical birth cohort modelled 
over 100 years using again equations (2) and (3) for modelling transitions in the population with 
and without type 1 diabetes. The differences from the model for the first five years are the 
assumptions that: the size of the population does not change (as those who die are replaced with 
individuals of the same age); and that the hypothetical cohort has received intensive treatment 
from the onset of type 1 diabetes, and hence has also been subject to lower transition 
probabilities from the onset of the disease.  In this model, the number of diabetic patients in 
each age group is the same as in the initial population of the model for the first five years, but 
they all have blood glucose under the recommended level and fewer of them have developed 
complications.  The ‘steady state’ model reflectes the delay between the intervention and its full 
benefits, estimating the reduction in burden of disease as if the current diabetic population was 
subject to treatment from the onset of diabetes and does not take into account recent predictions 
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of increasing future incidence rates [41].  It therefore underestimates the likely future burden of 
disease.  The initial population of the steady state model is a stable population, where everybody 
has blood glucose below the recommended level.  At the end of the year the population 
progresses according to transition probabilities characteristic of diabetic patients with glycaemic 
control.
Estimates of BoD in DALYs were estimated by equation (4) (using the same notation as 
equation (1)):
 YLDsYLLsDALYs
  
 


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0 0
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Data
As most death certificates of diabetic patients do not report diabetes as a cause of death, official 
statistics that report causes of mortality are unreliable for diabetes.  So we estimated mortality 
from diabetes using mortality rates from longitudinal studies [63, 65] and prevalence data from 
Harvey et al [60].  We estimated the presence and degree of severity of complications using the 
best evidence we could find, including studies conducted in the US or the Netherlands.  A 
systematic review of the evidence, although needed and valuable, was beyond the scope of this 
paper.  Details on the assumptions needed to deal with missing data are given in the last column 
of Table 2.
------------Table 2 Data sources and assumptions on missing data-------------------
The benefits of intensive glucose control are the difference between estimates of BoD with and 
without the intervention. In the absence of evidence on the level of disability from co-morbid 
conditions (e.g. retinopathy and nephropathy affecting the same person), we assumed that the 
disability from renal complications could be meaningfully added to the disability from eye and 
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foot complications, that is, for instance, the disability of a patient with both nephropathy and 
severe retinopathy contributes 0.29+0.43 YLDs (0.72 YLDs).  For comparison, this means that 
a year spent with diabetic nephropathy and severe visual impairments would have the same 
disability weight as, e.g., schizophrenia with several psychotic episodes and some permanent 
impairments, or a year of a child/adolescent in permanent stage with complex not curatively 
operable congenital heart disease.   Patients with all three complications at the highest degree of 
severity would contribute 0.91 YLDs (0.29+0.43+0.19). 
Our estimates of the potential net gain in output from intensive glucose control are based on 
estimated unit costs as outlined in Table 3 and Table 4.
-------------Table 3 Cost of monitoring glucose levels and prescribing insulin--------------
These costs assume the definition of intensive glucose control as it occurred in the original 
longitudinal study consisted of administration of insulin at least three times a day (or with an 
insulin pump); insulin dosage, dietary intake and exercise adjustment according to results of 
self-monitoring of blood glucose; self-monitoring of blood glucose at least four times per day; 
monthly measurement of HbA1c; monthly visit at the diabetic centre; and specialist calls during 
the month to review regimens. We ran three sensitivity analyses of our estimates of costs. First, 
we replaced monthly clinic visits with telephone calls from a specialist nurse, which is a more 
realistic assumption of what might happen outside research conditions and does not appear to 
reduce health benefits [68]. Second, we assumed the use of insulin pumps rather than multiple 
daily injections (although there is some evidence that insulin pumps are clinically more 
effective than multiple daily injections, most of the benefit is in terms of hypoglycaemic events 
or practical convenience and would not significantly affect microvascular complications). Third, 
we allowed for the cost of treating a diabetic patient to be about 30% higher than a non-diabetic 
one and about 27% above the average cost for the general population [69]. 
--------------Table 4 Cost of treating microvascular complications----------------
Results 
Health gains
Table 5 and the following Figures report annualised estimates for various measures of 
reductions in BoD and gains in DALYs.  
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The yearly estimates of the current BoD from type 1 diabetes in England was about 2,000 
deaths; 66,000 YLLs and 34,000 YLDs; 100,000 undiscounted and 63,000 discounted DALYs. 
In the first five years and the steady state the estimated benefits from intensive glucose control 
are reductions in the BoD of about: 10 and 400 deaths; 300 and 11,000 YLLs; 1,200 and 11,000 
YLDs; and 1,500 and 24,000 undiscounted DALYs; and 1,200 and 18,000 discounted DALYs.  
These are underestimates of the benefits as they do not include reductions in BoD from acute 
diabetes events (ketoacidosis), non-fatal myocardial infarctions, non-fatal strokes and coronary 
revascularisations, and this qualification also applies to our estimates of the monetary valuation 
of these benefits.  
---------------------Table 5 Burden of Disease and its reduction through intensive glucose control 
in the first five years and in the steady-state--------------
Figure 3 shows the BoD in undiscounted DALYs from type 1 diabetes and the estimated 
reductions in the first five years and in the steady state from intensive glucose control.  This 
shows that much of the current BoD from type 1 diabetes is unavoidable even with 100% 
compliance with intensive glucose control.  Figure 4 to Figure 7 show the distribution by age 
group of deaths, renal and eye diseases and amputations for the first five years and in the steady 
state. All these Figures bring out the common message that the benefits of intensive control 
appear to be much greater in the long run than the short run.  
-----------Figure 3 Estimates of BoD (undiscounted DALYs) from type 1 diabetes and reductions 
in the first five years and steady state from intensive glucose control-----------
-----------------Figure 4 ‘Avoidable’ deaths through intensive glucose control in the first five 
years and in the steady state by age at the beginning of the intervention---------------
-----------------Figure 5 ‘Avoidable’ cases of overt proteinuria and end-stage renal disease 
through intensive glucose control in the first five years and in the steady state by age at the 
beginning of the intervention------------
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-----------Figure 6 ‘Avoidable’ cases of severe visual disorders through intensive glucose 
control in the first five years and in the steady state by age at the beginning of the intervention
----------------Figure 7 ‘Avoidable’ cases of amputation through intensive glucose control in the 
first five years and in the steady state by age at the beginning of the intervention------------
Net costs and net gains in output
We estimated that:
 the annual cost to prescribe, monitor and treat microvascular complications of diabetes 
type 1 in England is currently about £380m (most of which is spent on monitoring the 
disease, prescribing insulin and treating renal complications (Table 6));
 the introduction of intensive monitoring increases the cost of insulin prescribing and 
monitoring by £350m and reduces the annual costs of complications by £20m in the 
first five years; and by £370m and £100m respectively in the steady state; 
 reductions in costs for eye diseases are mainly realized in the short run (£8m compared 
with long-run savings of £12m);
 reductions in costs for renal complications are mainly realized in the long run (£84m 
compared with short-run savings of £13m).  
------------Table 6 Annual costs and savings (negative figures) from intensive glucose control in 
the first five years and the steady state-----------
The estimates of costs and savings of intensive glucose control in the long run are of what these 
would be in a year: i.e. we have not examined these using discounting.  If the savings were 
discounted, these would be negligible because of the long time lags between the start of 
incurring the costs of intensive glucose control and making these savings from reduced use of 
health services.  In our estimates, the expected savings from reduced complication do not offset 
the increased cost for monitoring and prescribing.  There is, however, evidence that these costs 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
16
can be reduced. It is not necessary to have monthly visits to the diabetic clinic: a telephone 
discussion with a specialist nurse three times a week to adjust insulin dose and diet to the 
observed glucose levels was successful in reducing HbA1c below the recommended level at six 
months [68].  This practice would reduce the extra costs to about £270m and hence extra net 
costs to about £180m in the steady state.  
We used these costs in Table 7, which gives results from comparing costs and benefits in the 
short and in the long run.  This shows that the net cost of intensive glucose control in the short 
run are about six times larger than the monetary value of the health benefits.  If the intervention 
were to be introduced and sustained over its run-in period, however, the monetary value of 
health benefits would be three times the net cost of the intervention.
--------------Table 7 Net gain in output in the first five years and in the steady state-----------
Model validity
Assessing the validity of our model is difficult, because routinely available data usually refers to 
type 1 and type 2 diabetes combined (even when these labels are used, most patients belong to 
an ‘unspecified’ type of diabetes).  The available combined figures are likely to be a reflection 
of prevalence and incidence rates of diabetes type 2, which is about 90% of the diabetic 
population and is not representative of the population with type 1. In fact, type 1 typically has a 
much younger onset compared to diabetes type 2 and the duration of diabetes is one of the main 
risk factors of complications. Where data on type 1 diabetes exist, usually either there is no 
breakdown by age, or data are not for England, or they are not routinely available and hence 
could not be used as input for our initial condition. We now discuss how we compared the 
prevalence of complications resulting from our initial condition with data from the literature. 
Diabetic nephropathy
Table 8 compares prevalence rates of renal complications by degree of severity in our model 
and in the literature. Our estimates are generally consistent with data from empirical analysis, 
although we might overestimate the prevalence of end stage renal disease. The Renal Registry 
in England estimates that 30,000 people are receiving renal replacement therapy (including 
those who received a kidney transplant) and 5,000 started  renal replacement therapy in 2002 
[70]. Our model estimates that there are about 6,000 people with End Stage Renal disease and 
1,000 new cases per year among patients with type 1 diabetes which would correspond to about 
16% and 20% respectively of all patients receiving renal replacement therapy. This might be an 
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overestimate and we will indicate the health benefits and cost component separately for ESRD 
in the result section for transparency.
--------------Table 8 Prevalence rates of renal complications----------------
Diabetic retinopathy
Estimates of diabetic retinopathy for the population with type 1 diabetes vary greatly. A recent
literature review on prevalence reports rates between 0 and 84% for diabetic retinopathy in 
general; and between 1.1% and 25% for Proliferative Diabetic Retinopathy [71]. We report in 
Table 9 the prevalence of diabetic retinopathy in the WESDR study (which we used as a basis 
of our model) and the estimated prevalence based on the model by Davies et al. [72] who used 
the same dataset. Table 9 shows that our estimates are reasonable, once we assume the WESDR 
data can be used for England. Furthermore, the 9-year cumulative incidence of background 
diabetic retinopathy in our model is 81%, which is similar to estimates from the EAGLE model 
(77%), which also uses the WESDR study [73]. 
--------------Table 9  Prevalence rates of eye complications----------------
Diabetic foot
Health Episode Statistics (HES) report a total of 10,700 finished consultant episodes (FCEs) of 
amputation, including traumatic amputations and procedures associated with diabetic foot such 
as amputation of stumps. Our model predicts about 1,300 cases of amputation a year in the 
population with type 1 diabetes (toe and foot amputation) which would correspond to about 
12% of all amputation procedures conducted in England (including diabetes type 2 and non-
diabetic patients). From the publicly available HES data we could not identify what proportion 
of the total FCEs referred to people with type 1 diabetes. Results for diabetic foot are reported 
separately from those of renal and eye complications for transparency.
We compared our results with 4-year incidence rates of amputation and sores/ulcers in Moss et 
al. (1992) and show results in Table 10. Our prevalence estimates are based on the work by 
Moss and, as one should expect, the incidence rates correspond.  It is reassuring, however, to 
observe consistency in the overall incidence rate (last column in Table 10), which is an output 
of our model and our assumptions on those with different severities of retinopathy.
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We did not find data on prevalence or incidence of diabetic foot for the population with type 1 
diabetes in England to validate the diabetic foot model externally. Our model, however, 
estimates an annual incidence of 2.8% for sores/ulcers and 0.7% for amputation, which is 
similar to 2.1% and 0.6% mean national incidence rates for type 1 diabetes in the Netherlands 
[74].
--------------Table 10   4-year incidence rates of sores/ulcers and foot/toe amputations ------------
----
Intensive glucose control
We compare our model estimates on the relative risk of renal and eye complications with those 
in the DCCT study and in other diabetes models from the literature in table 11. Our model is 
consistent with the other studies in estimating the reduction in retinopathy and might slightly 
overestimate the reduction in renal complications by 15%. This overestimate does not have a 
significant impact on the estimate of the ‘avoidable’ Burden of Disease, which is mainly 
determined by a reduction in eye complications. The cost of renal complications, however, is 
the principal component of the savings in treating complications in the intensive care scenario in 
the steady state. Assuming a 15% lower savings from fewer renal complications, however, 
would not have an impact on the order of magnitude of our results: the net loss in the first five 
years would be unaffected and the net gain in the steady state would reduce from £350m to 
£330m.
Table 11 also reports estimates in the reduction of neuropathy, but our model does not model 
these complications explicitly. The relative risk in 9-year incidence of sores/ulcers and 
amputation in the intensive glucose control scenario is 0.95 and 0.91 which is much lower than 
the 0.47 relative risk of neuropathy at clinical examination in the DCCT study. A reduction in 
neuropathy does not imply an equivalent reduction in diabetic foot, however, the relatively 
small reduction in diabetic foot estimated in our model compared to the relatively high 
reduction in neuropathy indicates that we might have underestimated the ‘avoidable’ burden of 
disease.
--------------Table 11 Estimates of the risk reduction in 9-year incidence from microvascular 
complications ----------------
Costing
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The estimate of the current, annual cost of monitoring, prescribing and treating microvascular 
complications amounts to about £2,300 per patient. This is broadly consistent with a recent 
estimate of the total healthcare cost of treating people with type 1 diabetes in the UK by Currie 
et al. [75]. The annual healthcare cost of participants in their survey spent about £3,200 a year, 
including treatment and prevention of macrovascular complications such as stroke and 
myocardial infarction.
Our estimate for the current cost of treating renal complications and diabetic foot are also in line 
with other estimates of the cost for type 1 diabetes in the UK. The estimate of £175m for 
nephropathy is consistent with Gordois et al. [76] estimate of £152m (range £125-230m); the 
estimate of £8m for incident cases of diabetic foot seems consistent with the £35m (range £16-
61m) of prevalent cases of diabetic peripheral neuropathy [77].
Sensitivity analysis 
Our estimates of health benefits assume that the transition probabilities and mortality rates 
observed in longitudinal studies, in which the participants were generally between adolescence 
and middle age [40, 43, 44, 78-82], apply to the type 1 diabetes population in England, and the 
confidence interval estimates of mortality rates in older cohorts are particularly wide [63]. To 
test the robustness of the model to these assumptions, we estimated the effects of excluding 
from the analysis all people older than 75 years.  As this reduced these estimates by about one 
per cent, we concluded that they are robust to our assumptions of transition probabilities and 
mortality rates of older cohorts.
A crucial assumption in our estimates of the impacts of intensive glucose control is that there is 
compliance at levels comparable to those of the DCCT study. There is a linear relationship 
between the proportion complying and the reduction in BoD in DALYs. Figure 8 shows the 
estimated relationship for the steady-state model: a 1% increment in the proportion receiving 
intensive treatment and complying as in experimental conditions corresponds to a reduction of 
240 DALYs (or 180 discounted DALYs).  
-------------------Figure 8 Estimates of annual BoD in undiscounted DALYs from type 1 diabetes
in the steady state from 0 to 100% proportion of population complying with intensive glucose 
control--------------------
Another assumption worth testing is that of offering intensive glucose monitoring to all patients, 
including children and adolescents. On one hand, DCCT researchers were cautious about the 
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use of intensive glucose monitoring in children because of the increased risk of hypoglycaemic 
events. On the other, the low proportion of adolescents with glucose concentration below the 
recommended level  might signal the rebellion against parental or medical authority suggesting 
the possibility of very low compliance rates with intensive treatment. Our model, however, 
assumes that most microvascular complications arise after the age of 15 (with the exception of 
ulcers which we assume occurs at any age and amputation which we assume occurs only in 
people older than 30) and excluding these age groups from the analysis would not significantly 
impact on the estimates of health benefits: the estimate of the ‘avoidable’ burden of disease 
offering intensive glucose control only to people aged 20 or older is just 0.1% lower both in the 
short run and in the steady state. This result should be interpreted with caution because our 
Markov chain assumes that the incidence of microvascular complications from the age of 15 (or 
30 for amputation) is independent from glucose concentrations maintained in childhood and we 
did not find evidence to support or dismiss this assumption.  Clearly, however, the exclusion of 
children and adolescents from intensive glucose monitoring would have an impact on costs.  
The sensitivity analysis shows that the reduction in costs by providing intensive treatment only 
to patients who are 20 years old or older is 50m in the short run and 60m in the steady state 
which would imply a lower loss in net output in the first five years (£170m compared to £220 in 
the base case) and a higher net gain in output in the steady state (£410m compared to £350 in 
the base case).
To test the robustness of our cost estimates, we also assumed the use of insulin pumps to replace 
the base case assumption of multiple daily injections. There is growing interest in the use of 
insulin pumps as an alternative treatment to manage diabetes.  In comparison with multiple 
daily injections, insulin pumps improve quality of life in terms of their higher efficacy on 
controlling glucose concentration, of reducing incidence of adverse events (i.e. hypoglycaemic 
events) and their flexibility of lifestyle. However, they are not currently considered cost-
effective because of their higher cost [83].  If all patients use insulin pumps (using the average 
annual cost from Colquitt et al. [83]), the incremental cost of insulin prescribing and monitoring 
would be £515m in the short run (annualized figure over first 5 years) and £547m in the steady 
state.  This would consistently lower the net gains from Table 7; however, although this is an 
extreme and unrealistic assumption, the results would still be a loss in the short run (£470m net 
loss in output) and a gain in the steady state (£75 net gain in output).
We also assumed a cost of acute care (inpatient and outpatient) 27% higher than the national 
average cost [69]. Under this scenario, the estimate of the total current cost of insulin and 
microvascular complication increases from £370m to £515m per year; the increase in spending 
from intensive glucose monitoring reduces from £250m to £210m and from £180m to £105m in 
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the first five year model and in the steady state respectively assuming telephone discussion with 
a specialist nurse rather than monthly visits to the diabetes clinic; from £330m to £285m and 
from £270m to £190m in the first five years and in the steady state model assuming monthly 
visit as in the original DCCT study. This is as expected because the higher cost of acute care 
increases the savings from treating microvascular complications, and this determines a lower net
loss in the short run (£170m compared to £220m in the base case assuming monitoring with 
nurse on the phone) and a higher gain in net output in the steady state (£430m compared to 
£350m in the base case).
We ran a sensitivity analysis on the cost of peritoneal haemodialysis, assuming the use of 
continuous ambulatory peritoneal dialysis (CAPD) instead of continuous cyclic peritoneal 
dialysis (CCPD) which is cheaper although currently not considered cost-effective [84]. The 
resulting reduction in cost does not significantly affect results (£169m current cost vs. £162 in 
base case; same reduction in short run; 76m reduction nephropathy cost in steady state vs. £79 
base case cheap or £84 base case DCCT).
Finally we tested the monetary value of health benefits with two sensitivity analyses.  First, we 
use a lower figure of £20,000 as advocated by part of the literature [e.g. 85]. Second, we used 
the health benefits using the value of a statistical life (HM Treasury, 2003). Both sensitivity 
analyses confirm a net loss of more than £200m (£230 and £240 respectively) in the short run 
and a net gain above £180m in the steady-state (£180 and £260 respectively).
Discussion
This paper aimed to explore how disease models could be used in setting priorities for strategic 
commissioning for populations. To set priorities using evidence, it is essential to estimate
impacts of interventions at the level of populations, but this can only be done by disease 
modelling.  An obstacle to the use of such models is that they are often highly complex, demand 
rich sources of data, and take a long time to develop.  We have described the development of a 
parsimonious transparent model of the size and timing of costs and benefits of intensive glucose 
control in the type 1 diabetes population, which has produced approximate estimates that are 
adequate for priority setting as shown by validation and sensitivity analysis. This paper has 
shown, that:
 The current BoD from type 1 diabetes disease from microvascular complications and 
premature mortality is about 100,000 DALYs of which one third is attributable to low 
quality of life and two thirds to premature death. This is an underestimate of the current 
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burden of disease from diabetes type 1, because it does not include disability due to 
acute diabetic events (ketoacidosis), non-fatal myocardial infarctions, non-fatal strokes 
and coronary revascularisations.
 Introducing intensive glucose control, in the short run, will almost double the spend for 
monitoring glucose, prescribing insulin and treating microvascular complications but 
have small effect in reducing the burden of disease (a 1-2% reduction).
 Introducing intensive glucose control, in the long run, reduced the BoD by about 30%: 
with this being approximately equally divided into benefits from lower mortality and 
lower morbidity. The lower cost of treating complications in the long run will still not 
offset the increased cost of monitoring and insulin prescribing (50% higher than 
conventional care); however, the value of the health benefits more than compensates the 
increase in costs. 
The study also highlighted inadequacies in the data that are routinely collected in England: 
chronic diseases, such as diabetes, are frequently not reported on death certificates thereby 
masking the impact of long term consequences; there are significant gaps in data on the type of 
diabetes, age of the patient, duration of diabetes, presence of complication with degree and 
duration, sex and current treatment regime. In England many of these data are in principle 
available for purchase from the General Practice Research Database that offers a sample of 
about 7,500-8,000 type 1 diabetes patients, that is about 4.5% of the total type 1 diabetes
population [63, 64].  These data ought to be collected in disease registers to support evidence-
based policy making.  An initiative that has the potential to provide this information in England 
is the current national Programme for IT in the NHS, Connecting for Health.
The final point concerns the approach to modelling illustrated by this paper.  In setting 
priorities, information on costs and benefits in the short and long run for options for type 1 
diabetes is obviously insufficient.  We have applied our approach to a number of different 
interventions: suicide prevention, treatment of depression, prescribing of statins to reduce 
cholesterol, and various options for the prevention and treatment of strokes [86].  In all this 
work, it seems to us that relatively simple models, similar to that in this paper described for type
1 diabetes have been adequate in making comparisons for setting priorities for strategic 
commissioning. Indeed we see the key next step as not the development of more complex 
models for each of these but developing a simple method to generate adequate estimates for the 
wide range of interventions that must be considered by strategic commissioners.
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Appendix
Model parameters
------- Table A1, A2, A3, A4 and A5  about here -------------------------
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Figures
Figure 1 Proportion of type 1 diabetes population with glucose levels within the recommended level, 
by age group
Diabetes Type 1 population with glucose under control
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Source:(National Clinical Audit Support Programme, 2005), data breakdown provided upon request by NHS –
Health and Social Care Information Centre
Figure
Figure 2 Base structure of the model for diabetic nephropathy (left) and diabetic retinopathy & diabetic 
foot (right)
Diabetic nephropathy model
r0 Normo-albuminuria
r1 Microalbuminuria (urinary albumin excretion 40 mg/24 hr)
r2 Macroalbuminuria or overt-proteinuria (urinary albumin excretion 300 mg/24 hr)
r3 End-Stage-Renal-Disease (ESRD)
Progression Diabetic patients move through disease states according to annual transition probabilities. 
See table A3 in Appendix 2.
Mortality All-cause mortality.  
Diabetic retinopathy
e0 No retinopathy
e1 Background diabetic retinopathy (BDR)
e2 Proliferative diabetic retinopathy (PDR)
e3 Severe visual loss
Progression Diabetic patients move through disease states according to annual transition probabilities. 
See table A4 in Appendix 2.
Mortality All-cause mortality.
Diabetic foot
fs Sores /Ulcers
fa Amputation
YLDs
+
Years lived in each state s weighted for the disability associated with the state.
DALYs
YLLs Years of Life Lost to premature (excess) mortality attributable to diabetes
1.
                                                     
1 Deaths in the diabetic population are caused by ‘normal’ mortality, i.e. mortality rate as in the non-diabetic population, and ‘excess’ 
mortality due to diabetes.  Only ‘excess’ mortality generates Years of Life Lost (YLLs) for the Burden of diabetes estimate.  
Figure 3 Estimates of BoD (undiscounted DALYs) from type 1 diabetes and reductions in the first 
five years and steady state from intensive glucose control
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Figure 4 ‘Avoidable’ deaths through intensive glucose control in the first five years and in the steady 
state by age at the beginning of the intervention
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Figure 5 ‘Avoidable’ cases of overt proteinuria and end-stage renal disease through intensive glucose 
control in the first five years and in the steady state by age at the beginning of the intervention
Renal complications - annual reduction from intervention
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Figure 6 ‘Avoidable’ cases of severe visual disorders through intensive glucose control in the first five 
years and in the steady state by age at the beginning of the intervention
Eye complications - annual reduction from intervention
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Figure 7 ‘Avoidable’ cases of amputation through intensive glucose control in the first five years and in 
the steady state by age at the beginning of the intervention
Amputations of toe or foot - annual reduction from intervention
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Figure 8 Estimates of annual BoD in undiscounted DALYs from type 1 diabetes in the steady state 
from 0 to 100% proportion of population complying with intensive glucose control.
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Tables
Table 1 Main model assumptions
Assumption Justification
The transition probabilities from state i depend 
only on being in state i and not on the history 
before arriving in state i.
This is the standard simplifying assumption in 
modelling stochastic processes and is the basis of 
Markov chain models that are widely used in 
modelling progression of disease and is common 
practice for modelling diabetes. To relax this 
assumption we divide the population in 5-year 
age groups and use a different set of transition 
probabilities for each one if data was available.
Same rates apply to men and women. With the exception of myocardial infarction 
complication rates are similar in men and women 
(National Clinical Audit Support Programme, 
2005). 
Under the intervention scenario, all the diabetic 
population is subject to intensive treatment.
This reflects NICE recommendations to maintain 
HbA1c7.5% in all diabetic patients, but will 
overstate the benefit of the intervention.  We 
used sensitivity analysis on compliance rates to 
test this assumption.
Table
Table 2 Data sources and assumptions on missing data
Information Source Description/Evaluation Assumptions on missing data
Incidence

(National 
Clinical 
Audit 
Support 
Programme, 
2005)
This is an overview of diabetes 
and diabetes care in England. 
Coverage is partial: about 22% of 
eligible PCTs, GP practices and 
Hospitals registered; about 34% 
of paediatric units.
It gives data for 0-16 years old.
We assumed diabetes onset is 
before age 35 using the incidence 
rate for 0-16 also for people 17-35 
years old.  This assumption implies 
a slight overestimate of the burden 
of diabetes in the model for the 
first five years.
We made the standard assumption 
that all Type 1diabetic patients are 
diagnosed.
Current 
population 
with Type 1 
Diabetes by 
age group 
A(0,j)
(Harvey et 
al., 2002, 
Diabetes UK, 
2004b, a, 
Health and 
Social Care 
Information 
Centre, 
2004);
details for 
(Health and 
Social Care 
Information 
Centre, 
2004)
provided by 
NHS –
Health and 
Social Care 
Information 
Centre
(Diabetes UK, 2004b) gives 
estimates for the 17,000 children 
with Type 1 Diabetes which are 
based on audited data of about 
10,000 children.
(Diabetes UK, 2004a) estimates 
the diabetic population but in 
wide age bands.
(Health and Social Care 
Information Centre, 2004) is the 
QOF data at GP level (carefully 
audited as the basis for the new 
GMS contract) and reports the 
total number of diabetic patients 
in the surgery (but lacks details 
on type of diabetes and age).
(Harvey et al., 2002) reports age-
specific prevalence estimates of 
Type 1 Diabetes for the County 
of Clwyd in North Wales.
There is no single definitive source 
of audited prevalence data of Type 
1 Diabetes for all age groups.
We used the (Harvey et al., 2002).  
This assumes that the estimates are 
representative for England.
Information Source Description/Evaluation Assumptions on missing data
Number of 
people by 
degree of 
severity s
(Klein et al., 
1989b, a, 
Klein et al., 
1989c, 
Diabetes 
Control and 
Complication 
Trial, 1990, 
1993, Klein
et al., 1994, 
Diabetes 
Control and 
Complication 
Trial, 1996, 
Rossing et 
al., 1996, 
Brailsford et 
al., 1998, 
Klein et al., 
1998, Davies
et al., 2001, 
Niessen, 
2002, 
Soedamah-
Muthu et al., 
2006a)
These data do not refer to the 
English population and some are 
ten years old.  Most of these 
sources report transition 
probabilities based on 
longitudinal studies but the 
original dataset of the study is 
not available.  Data are usually 
reported for the whole population 
in the study or for wide age 
groups.
We needed to make some heroic 
assumptions to generate the initial 
distribution of diabetic population 
across degrees of severity of renal 
and eye disease complications.
We used our model to generate a 
sample population of 100,000 
susceptible and projected it over 
100 years.  We assumed that the 
proportion of people in each degree 
of severity for each age was 
representative of the current 
population of that age.  We applied 
these proportions to the A(0,j) as 
estimated above.
Transition 
probabilities 
in 
nephropathy 
(excluding 
mortality 
rates)
(Diabetes 
Control and 
Complication 
Trial, 1990, 
1993, 1996, 
Niessen, 
2002)
(Niessen, 2002) developed 
Markov chain models of diabetes 
complications, also on the DCCT 
study . The DCCT study was a 
major, multi-centre study of 
1,441 diabetic patients in the US, 
lasted nine years.  The study 
quantifies the effect of intense 
treatment on progression in 
microvascular sequelae. 
These data do not refer to the 
English population and some are 
ten years old.  They report 
transition probabilities based on 
longitudinal studies but the 
original dataset of the study is 
not available.  Data are usually 
reported for the whole population 
in the study or for wide age 
groups.
We assumed that the transition 
probabilities apply to the current 
diabetic population in England.
Mortality 
rates in 
nephropathy 
model
(Diabetes 
Control and 
Complication 
Trial, 1996, 
Rossing et 
al., 1996, 
Soedamah-
Muthu et al., 
2006a)
(Rossing et al., 1996) is a cohort 
study of a 10-year observational 
follow up of 939 adult patients 
with insulin dependent diabetes 
in Denmark. 
(Soedamah-Muthu et al., 2006a)
gives all cause mortality rates 
from the General Practice 
Research Database. This is a 
reliable source of data of for 
England, based on a 7-year 
longitudinal study of 7,713 
patients with Type 1 Diabetes  .
We used an average between 
(Diabetes Control and 
Complication Trial, 1996, Rossing
et al., 1996). The aggregate 
mortality rate is similar to that in 
(Soedamah-Muthu et al., 2006a), 
which could not be used directly 
because does not specify 
complications severity.
Information Source Description/Evaluation Assumptions on missing data
Transition 
probabilities 
in 
retinopathy 
(including 
mortality 
rates)
(Klein et al., 
1989b, a, 
Klein et al., 
1989c, Klein
et al., 1994, 
1998, Davies
et al., 2000, 
Davies et al., 
2001)
The DCCT study had a high 
degree of uncertainty on its 
incidence estimate for 
retinopathy because only a small 
group of participants who did not 
have retinopathy at baseline 
stayed in the study for 9 years 
(Mount Hood 4 Modeling Group, 
2007).
We used another study on the 
progression of retinopathy in our 
model, the Wisconsin 
Epidemiologic Study of Diabetic 
(WESDR) Retinopathy following 
Davies et al.(2000).
WESDR data do not refer to the 
English population and are 
fifteen years old.  They report 
transition probabilities based on 
longitudinal studies but the 
original dataset of the study is 
not available.  Data are usually 
reported for the whole population 
in the study or for wide age 
groups.
We assumed that the transition 
probabilities apply to the current 
diabetic population in England.
Incidence 
rates of 
amputations, 
sores or 
ulcers
(Moss et al., 
1992)
(Moss et al., 1992) provide 4-
year incidence rate of amputation 
and sores or ulcers by 
characteristics of the population, 
including the presence and 
degree of severity of diabetic 
retinopathy (p<.0001)
We assumed that the incidence 
rates from each degree of 
retinopathy apply to the current 
diabetic population in England.
Mortality 
rates non 
diabetic 
population
(Soedamah-
Muthu et al., 
2006a)
Data about the non-diabetic 
population refers to a control 
group matching the diabetic 
population under study and is not 
representative of the general non-
diabetic population.
We used (Soedamah-Muthu et al., 
2006a)‘s age-specific mortality 
rates for the population with Type 
1 Diabetes  to generate the 
expected deaths in one year.  We 
subtracted this data from the total 
number of deaths from all causes 
per age group as in (Office of 
National Statistics, 2003) and 
derived mortality rates for the non-
diabetic population.
Disability 
weights
(Stouthard et 
al., 1997)
The disability weights were 
estimated by the Dutch study that 
developed disability weights 
applicable to developed 
countries. 
In the absence of disability weights 
in the presence of co-morbid 
conditions we assumed that the 
weights are additive.
5Table 3 Cost of monitoring glucose levels and prescribing insulin
Conventional treatment Intensive treatment*
Item
unitary cost items per 
year
annual cost 
per diabetic 
patient
items per 
year
annual cost 
per diabetic 
patient
lancets £0.07 730 £51 1,278 £89
glucose test 
stripes
£0.87 730 £633 1,278 £1,107
glucometer £40.00 0 £11 0 £11
insulin £0.26 730 £190 1,278 £332
insulin 
syringes
£0.15 730 £110 1,278 £192
insulin pen £15.00 0 £4 0 £4
diabetes 
clinic visits
£106.00 1 £106 12 £1,272
nursing staff £34.00 - £- 9 £295
total £1,105 £3,303
*When we run the model replacing monthly visit with specialist nurses on the phone, we 
change the intensive treatment assuming one annual visit at the clinic and three telephone 
conversations per week of 10 minutes each with the specialist nurse, for a total cost of intensive 
treatment of £2,726 per patient per year; when we tested the cost implications of using insulin 
pumps, we used the average annual cost of the pump and consumables (including savings from 
reduced use of insulin) from a recent Health Technology Assessment study (Colquitt et al., 
2004) assuming monitoring was provided through telephone conversation with a specialist 
nurse, for a total annual cost of £4,333 per patient per year.
6Table 4 Cost of treating microvascular complications
conventional care intensive care#
Degree of 
severity
Data source
cost 1st year
cost following 
years
cost 1st year
cost following 
years
microalbuminuria
(Gordois et al., 
2004)
£44a £44a £44a £44a
macroalbuminuri
a
(Gordois et al., 
2004)
£4,215a,b,c £4,215a,b,c £3,791a,b £3,791a,b
End Stage Renal 
Disease -
dialysis
(MacLeod et 
al., 1998, 
Mowatt et al., 
2003, 
Department of 
Health, 2004a, 
Gordois et al., 
2004)
£21,152d £21,152d £21,152d £21,152d
End Stage Renal 
Disease -
transplant
(Department of 
Health, 2004a)
£18,727e £240e £18,727e £240e
Background 
Diabetic 
Retinopathy
(Department of 
Health, 2004a)
£89 £55 £- £-
Proliferative 
Diabetic 
Retinopathy 
visits
(Department of 
Health, 2004a)
£89 £55 £- £-
Laser treatment
(Department of 
Health, 2004a)
£602 £- £602 £-
PDR cost
visit + laser 
treat at onset
£691 £55 £602 £-
Severe vision 
loss (blind one 
eye)
(Clarke et al., 
2003)
£872 £281 £872 £281
Sores/ulcers
(Department of 
Health, 2004a)
£162f £45f £162f £-
Amputation
(Department of 
Health, 2004a)
£6,248g £73g £6,248g £73g
#
The cost in the intensive treatment scenario is lower because we assumed that the monthly visit at the diabetes clinic is a substitute for 
routine follow-up visits after complications. When we run the model with the less expensive intervention we used the costs reported 
under ‘conventional treatment’ also for the intensive treatment scenario
a
 ACE inhibitor (Captopril 25mg, 4/day)
b
 epoetin alfa (3,000U, 3/week)
c
 four outpatients clinic visits per year
d
 £24,960 annual cost for hospital haemodialysis (20.5% of cases), £21,000 for haemodialysis in satellite units (20.5% of cases), £19,300 
for  home haemodialysis (1% of cases), £17,828 peritoneal dialysis COPD (22% of cases). Number of cases are those reported in Annual 
report of Renal Registry (Ansell et al., 2003).
e
cost of transplant and four post-transplant visits in first year; one post-transplant visit per year thereafter
f
 treatment for skin disorder followed by yearly podiatrist visits
g
 average cost of amputation (elective and non elective) weighted by number of Finished Consultation Episodes in first year and cost of 
orthopaedic follow up visit thereafter.
7 Table 5 Burden of Disease and its reduction through intensive glucose control in the first five years 
and in the steady-state
Burden of disease with 
current care
(current BoD)
Short term
burden reduction
from intensive glucose 
control (100% compliance)
First 5 years 
(annualized)
First year 
only 
(sensitivity 
analysis)
First 5 years 
(annualized)
First year 
only 
(sensitivity 
analysis)
Steady 
state:
burden 
reduction
from 
intensive 
glucose 
control 
(100% 
compliance)
Deaths (‘000s) 2 2 0.01 0 0.4
Monetary 
value of 
deaths (£m)
2,300 2,300 9 0 440
YLLs (‘000s) 66 65 0.3 0 11
YLDs from 
renal 
complications 
(‘000s)
8* 7 0.2 0 3**
YLDs from eye 
complications 
(‘000s)
23 23 0.9 0.3 8
YLDs from 
diabetic foot 
(‘000)
3 1# 0 0 0.4
YLDs total 
(‘000)
34 31 1.2 0.3 11
DALYs (‘000s) 
(undiscounted) 
100 96 1.5 0.3 23.5
DALYs (‘000s) 
(discounted) 
63 64 1.2 0.3 17.8
Monetary 
value of 
DALYs averted 
(discounted, 
£m)
1,900 1,900 35 9 535
* of which 2 from ESDR
** of which 1 from ESDR
# incident cases only, hence annualized figure for first 5 years is higher
8Table 6 Annual costs and savings (negative figures) from intensive glucose control in the 
first five years and the steady state
Conventional care 
(current spend)
in £ m
Intensive glucose control 
assuming monthly visit at 
diabetic clinic as in original 
DCCT study
Intensive glucose control 
replacing monthly visits 
with more frequent 
telephone supervision by 
specialist nurse
In first 
year
In first five 
years 
(annualized)
First five 
years: 
change in 
expenditure
(annualized)
in £ m
Steady 
state: 
change in 
expenditure
in £ m
First five 
years: 
change in 
expenditure 
(annualized)
in £ m
Steady 
state: 
change in 
expenditure
in £ m
Insulin 
prescription 
and glucose 
monitoring
187 175 + 349 + 373 +257 +275
Treatment 
of 
nephropathy
175 169 - 13 - 84 -6 -79
Treatment 
of 
retinopathy
14 14 - 8 - 12 -2 -9
Treatment 
of diabetic 
foot
8 8 - 0.5 - 4 -0.5 -4
Expenditure 383 366 + 328 + 272 +249 +182
9Table 7 Net gain in output in the first five years and in the steady state
Intervention in 
first five years
 in £m
Intervention in the 
steady state
 in £m
Monetary value of DALYs 
averted (at £30k per DALY, 
discounting YLLs)
30 530
Extra costs 250 180
Gain (loss) in output (220) 350
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Table 8. Prevalence estimates of renal complications by severity.
Normo-
albuminuria 
prevalence
Micro-
albuminuria 
prevalence
Macro-
albuminuria 
prevalence
End Stage 
Renal Disease 
prevalence
Model estimates 
(conventional 
care)
57% 28% 11% 4%
(Harvey et al., 
2001; n=1,297; 
Wales, UK)
61.4%
At 15-29 years 
duration: 
27.2%;
Below 5 years 
duration: 14%
11% 1.8%
DARTS (2001) n/a n/a n/a 1%
Finne et al. (2005)
(n=20,005; 
Finland)
n/a n/a n/a
Cumulative 
incidence at 20 
years from 
onset = 2.2%; at 
30 years from 
onset = 7.8%
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Table 9. Prevalence estimates of eye complications by severity.
No retinopathy
Background 
Diabetic 
Retinopathy
Proliferative 
Diabetic 
Retinopathy
Severe visual 
loss 
(including 
blindness)
Model estimates 
(conventional 
care)
26% 40% 23% 8%
(Klein et al., 
1984; US)
30%
46% 
(of which 17% 
severe non-
proliferative 
diabetic 
retinopathy)
14% 9%
(Davies et al., 
2001)
20% 49%
30%
(25% PDR and 5% untreatable)
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Table 10. 4-year incidence rates of sores/ulcers and foot/toe amputation.
4-year incidence of sores/ulcers
In patients with 
no retinopathy
In patients with 
mild or 
moderate 
retinopathy
In patients with 
PDR
All patients
Model estimate 
(conventional 
care)
5.6% 9% 18.7% 11.5%
Moss et al. 
(1992)
5.8%
(n=273)
9%
(n=440)
18.3%
(n=166)
9.5%
(n=879)
4-year incidence of amputation
In patients with 
no retinopathy
In patients with 
mild or 
moderate 
retinopathy
In patients with 
PDR
All patients
Model estimate 
(conventional 
care)
0% 1.4% 8% 3%
Moss et al. 
(1992)
0%
(n=273)
1.4%
(n=440)
7.8%
(n=166)
2.2%
(n=879)
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Table 11 Estimates of risk reduction in 9-year incidence of microvascular complications 
(source: Mount Hood 4 Modeling Group, 2007)
DCCT study Our model
EAGLE 
model
CORE 
model
Archimedes 
model
Microalbuminuria 0.59 0.68 0.61 0.54 0.53
BDR 0.27 0.33 0.90 0.37 0.32
Neuropathy 0.47 n/a 0.29 0.39 n/a
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Table A1 Parameters shared by the renal and eye disease model: mortality rate of the 
non-diabetic population and incidence rate of diabetes
age  
under 1 5.457821 0.000149
1_4 0.237416 0.000149
5_9 0.101432 0.000149
10_14 0.119732 0.000149
15_19 0.327034 0.000149
20_24 0.493336 0.000149
25_29 0.547027 0.000149
30_34 0.718174 0.000149
35_39 0.966249 0
40_44 1.506267 0
45_49 2.376491 0
50_54 3.811951 0
55_59 5.864163 0
60_64 9.851112 0
65_69 15.91389 0
70_74 26.90164 0
75_79 46.63052 0
80_84 76.82135 0
85+ 172.5086 0
Table A2 Incidence rates of sores/ulcers and amputation
Degree of severity of 
retinopathy
Incidence of sores 
and/or ulcers
Incidence of lower 
extremity amputation
No retinopathy 1.45% 0%
Mild or Moderate retinopathy 2.25% 0.35%
Proliferative Diabetic 
Retinopathy
3.66% 1.95%
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Table A3 Transition probabilities in the renal disease complication model
Transition probabilities
Excess mortality Intensive glucose control Conventional care
age ’(s0) ’(s1) ’(s2) ’(s3) 0->1 1->2 2->3 0->1 1->2 2->3
under 1 0.006092 0.008683 0.011820 0.000000 0 0 0 0 0 0
1_4 0.005047 0.006595 0.008166 0.000000 0 0 0 0 0 0
5_9 0.005020 0.006541 0.008071 0.000000 0 0 0 0 0 0
10_14 0.005024 0.006548 0.008084 0.000000 0 0 0 0 0 0
15_19 0.005065 0.006631 0.008229 0.000000 0.022 0.02 0.05 0.034 0.06 0.05
20_24 0.005099 0.006697 0.008345 0.030809 0.022 0.02 0.05 0.034 0.06 0.05
25_29 0.005109 0.006719 0.008383 0.030755 0.022 0.02 0.05 0.034 0.06 0.05
30_34 0.005144 0.006787 0.008503 0.030584 0.022 0.02 0.05 0.034 0.06 0.05
35_39 0.005193 0.006886 0.008676 0.107831 0.022 0.02 0.05 0.034 0.06 0.05
40_44 0.005301 0.007103 0.009054 0.107291 0.022 0.02 0.05 0.034 0.06 0.05
45_49 0.005475 0.007451 0.009664 0.106420 0.036 0.03 0.05 0.057 0.03 0.05
50_54 0.005762 0.008025 0.010668 0.145978 0.036 0.03 0.05 0.057 0.03 0.05
55_59 0.006173 0.008846 0.012105 0.143926 0.036 0.03 0.05 0.057 0.03 0.05
60_64 0.006970 0.010440 0.014896 0.176940 0.036 0.03 0.05 0.057 0.03 0.05
65_69 0.008183 0.012866 0.019140 0.195137 0.036 0.03 0.05 0.057 0.03 0.05
70_74 0.010380 0.017261 0.026831 0.184149 0.036 0.03 0.05 0.057 0.03 0.05
75_79 0.014326 0.025152 0.040641 0.164420 0.036 0.03 0.05 0.057 0.03 0.05
80_84 0.020364 0.037229 0.061775 0.134229 0.036 0.03 0.05 0.057 0.03 0.05
85+ 0.039502 0.075503 0.128756 0.128756 0.036 0.03 0.05 0.057 0.03 0.05
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Table A4 Transition probabilities in the eye disease complication model
Excess mortality Intensive glucose control Conventional care
age ’(s0) ’(s1) ’(s2) ’(s3) 0->1 1->2 2->3 0->1 1->2 2->3
under 1 0.0015 0.005 0.033186732 0.0331867 0 0 0 0 0 0
1_4 0.0015 0.005 0.025356124 0.0253561 0 0 0 0 0 0
5_9 0.0015 0.005 0.025152148 0.0251521 0 0 0 0 0 0
10_14 0.0015 0.005 0.025179598 0.0251796 0 0 0 0 0 0
15_19 0.0015 0.005 0.025490551 0.0254906 0.039 0.02544 0.01855 0.13 0.048 0.035
20_24 0.0015 0.005 0.025740004 0.02574 0.039 0.02544 0.01855 0.13 0.048 0.035
25_29 0.0015 0.005 0.025820541 0.0258205 0.039 0.02544 0.01855 0.13 0.048 0.035
30_34 0.0015 0.005 0.026077261 0.0260773 0.039 0.02544 0.01855 0.13 0.048 0.035
35_39 0.0015 0.005 0.026449374 0.0264494 0.039 0.02544 0.01855 0.13 0.048 0.035
40_44 0.0015 0.005 0.027259401 0.0272594 0.039 0.02544 0.01855 0.13 0.048 0.035
45_49 0.0015 0.005 0.028564737 0.0285647 0.039 0.02544 0.01855 0.13 0.048 0.035
50_54 0.0015 0.005 0.030717927 0.0307179 0.039 0.02544 0.01855 0.13 0.048 0.035
55_59 0.0015 0.005 0.033796245 0.0337962 0.039 0.02544 0.01855 0.13 0.048 0.035
60_64 0.0015 0.005 0.039776668 0.0397767 0.039 0.02544 0.01855 0.13 0.048 0.035
65_69 0.0015 0.005 0.048870835 0.0488708 0.039 0.02544 0.01855 0.13 0.048 0.035
70_74 0.0015 0.005 0.06535246 0.0653525 0.039 0.02544 0.01855 0.13 0.048 0.035
75_79 0.0015 0.005 0.09494578 0.0949458 0.039 0.02544 0.01855 0.13 0.048 0.035
80_84 0.0015 0.005 0.140232025 0.140232 0.039 0.02544 0.01855 0.13 0.048 0.035
85+ 0.0015 0.005 0.2837629 0.2837629 0.039 0.02544 0.01855 0.13 0.048 0.035
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Table A5 Disability weights
Health state
Disability weight 
(95% C.I)
Health state description in 
disability weight source
Corresponding EQ 
5D+ classification
Source
No complications 0.07 (0.047-0.094)
“Uncomplicated diabetes 
mellitus”
111111 (90%), 
112221 (10%)
Stouthard et al. 1997, p.73
Macroalbuminuria and ESRD 0.29 (0.201-0.380)
“Diabetes mellitus with 
nephropathy”
112121 (80%), 
113231 (20%)
Stouthard et al. 1997, p.73
Moderate retinopathy (BDR, non 
severe PDR)
0.17 (0.073-.278)
“[Diabetes mellitus with] 
moderate [vision disorders] (i.e., 
great difficulty reading small 
newspaper print, some difficulty 
recognizing faces at 4m. 
distance”
112121 Stouthard et al. 1997, p.75
Severe retinopathy 0.43 (0.339-0.521)
“[Diabetes mellitus with] severe 
[vision disorders] (i.e. unable to 
read small newspaper print, 
great difficulty or unable to 
recognize faces at 4m. 
distance)”
123121 Stouthard et al. 1997, p.75
Sores, ulcers and
Lower extremity amputation
0.19 (0.128-0.255)*
“[Diabetes mellitus] with 
neuropathy”
111111 (75%), 
222221 (20%), 
222331 (5%)
Stouthard et al. 1997, p.73
*the global burden of disease study uses 0.3 for foot amputation and 0.102 for toe amputation (Murray and Lopez, 1996); there is no disability weight for amputation in the paper by 
Stouthard et al. (1997) which we used as the main source for weights in our study. The 0.19 weight for neuropathy in the Stouthard et al. paper is an average across different degree 
of severity and we use it both for sores/ulcers and amputations.
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